KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Revenue: 2018-2025

Historic Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Sep 2025 value amounting to $94.0 million.

  • Adaptive Biotechnologies' Revenue rose 102.38% to $94.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $252.8 million, marking a year-over-year increase of 42.57%. This contributed to the annual value of $179.0 million for FY2024, which is 5.10% up from last year.
  • Per Adaptive Biotechnologies' latest filing, its Revenue stood at $94.0 million for Q3 2025, which was up 59.60% from $58.9 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Revenue ranged from a high of $94.0 million in Q3 2025 and a low of $7.7 million during Q2 2023.
  • Moreover, its 3-year median value for Revenue was $45.8 million (2023), whereas its average is $46.7 million.
  • In the last 5 years, Adaptive Biotechnologies' Revenue tumbled by 82.36% in 2023 and then skyrocketed by 460.91% in 2024.
  • Adaptive Biotechnologies' Revenue (Quarterly) stood at $37.9 million in 2021, then skyrocketed by 45.53% to $55.2 million in 2022, then dropped by 17.05% to $45.8 million in 2023, then climbed by 3.66% to $47.5 million in 2024, then surged by 102.38% to $94.0 million in 2025.
  • Its Revenue stands at $94.0 million for Q3 2025, versus $58.9 million for Q2 2025 and $52.4 million for Q1 2025.